Acute lymphoblastic leukaemia study day

This study day is being organised by Amgen.
Elaine will deliver the morning session, covering:

Part 1:
The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
• A bit about B cells
• Genetic drivers of ALL
• Clonal evolution & intratumoural heterogeneity
• The role of leukaemic stem cells

Treating Philadelphia Chromosome Positive ALL
• Bcr-Abl inhibitors
• Other treatments

Part 2:
Licensed and novel treatments for ALL
• Blinatumumab
• Inotuzumab ozogamicin
• CAR-modified T cells
• Other treatments in trials

Contact Elaine if you would like to know how to book a place.

View the programme